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RLung  cancer  is  the  leading  cause  of  cancer-related
mortality in  Canada  and  USA  [1].  The  American  Can-
cer Society  has  estimated  that  in  2011  over  200  000
patients will  be  newly  diagnosed  with  lung  cancer,
more than  15  000  patients  will  die  of  this  disease.
Non-small  cell  lung  cancer  (NSCLC)  accounts  for
approximately  87%  of  lung  cancers  [2,3].
For last  decades  systemic  chemotherapies  espe-
cially platinum  based  doublets,  have  been  used
to treat  NSCLC,  but  outcome  improvements  have
reached  a  plateau  [4,5].  The  medium  survival
when platinum-based  doublets  are  administered  for
advanced NSCLC  has  improved  from  4 to  5 months
if untreated  to  8—10  months,  but  this  treatment
causes signiﬁcant  toxicities,  which  limit  the  number
of cycles  to  be  administered  [6].
Current  treatment  algorithms  for  the  treatment
of NSCLC  recommend  both  histologic  and  molecular
diagnostics  [7].  Recent  advances  in  our  under-
standing of  malignant  cell  signaling  pathways,  their
interconnections,  importance  of  different  recep-
tors, biomarkers,  and  the  interplay  between  various
oncogenes  have  led  to  the  development  of  tar-
geted  treatments  which  are  improving  efﬁcacy  and
also the  treatment  safety.  These  treatments  are
aimed at  speciﬁc,  especially  genetic  changes  of  the
malignant cells.  Different  NSCLC  subtypes  are  asso-
ciated with  potentially  targetable  biomarker  such
as epidermal  growth  factor  receptor  (EGFR)  muta-
tions [8—12]  —  KRAS  mutations  [13]  —  echinoderm
microtubule  —  associated  protein  like  4  (EML4),
anaplastic lymphoma  kinase  (ALK)  or  fusion  genes
(EML4—ALK)  [14,15]  and  c-MET  over  expression  or
ampliﬁcation  [16—19].
Our  hope  is  to  apply  the  knowledge  of  the  treat-
ments with  targeted  agents  acquired  in  advanced
stages of  NSCLC  to  the  earlier  stages  of  NSCLC,  too,
thus being  able  to  increase  the  NSCLC  cure-rate.
Combining different  targeted  agents  or  sequencing
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http://dx.doi.org/10.1016/j.jiph.2012.09.006hem  properly  will  be  very  important  in  the  new  era
f targeted  individualized  therapy.
In this  publication,  we  will  describe  the  impor-
ance of  a team  work  from  obtaining  the  tumor
issue, pathological  diagnosis,  molecular  analysis,
taging of  the  disease,  the  different  treatments  all
he way  to  supportive  care.  You  will  learn  about
he different  interventional  procedures  in  order  to
btain a satisfactory  tumor  specimen  for  analysis  by
athologist and  molecular  biologists,  to  radiation
nd medical  oncologist’s  treatments  and  ending
ith supportive  care  of  patients.  By  this,  we  hope  to
ive a complete  review  and  guidelines  for  present
nd future  approach  to  NSCLC  patients.
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